Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03669146
Other study ID # NEW-33235
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 24, 2019
Est. completion date January 5, 2023

Study information

Verified date February 2023
Source Ohio State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Infants do not usually wear glasses because they usually do not need them to see clearly. Most infants are born with a moderate amount of farsightedness. Most infants then undergo a natural process called 'emmetropization' that reduces the amount of farsightedness. However, up to 10% of infants don't emmetropize and end up with very farsighted prescriptions. Farsighted infants must use extra focusing effort to see clearly, which may make their eyes cross and perhaps cause a "lazy eye". If infants avoid this effort and their vision stays blurred into childhood, they may develop two lazy eyes. Farsightedness in school-aged children makes reading and learning more difficult. New studies in animals and in humans show that infant eyes will emmetropize best if they have just a normal, moderate amount of farsightedness. The infant eye must be in this normal target zone in order to emmetropize. If a baby were given glasses with the full prescription to correct all of his farsightedness, the eyes would also be out of the target zone and would not receive any signal to grow. The best strategy might be to give a partial spectacle correction for the farsightedness, just enough to put them in the zone that is most effective for emmetropization. The purpose of this project is to determine if emmetropization can be enhanced in very farsighted babies. We will give them glasses with a partial correction and accommodative (eye focusing) training. The partial correction is an amount that is less than their full degree of farsightedness but enough to put them in the zone of effective emmetropization. As changes in farsightedness occur, the power of the glasses will be reduced to keep the farsightedness within the target zone. If an infant reaches a normal amount of farsightedness, the glasses will be discontinued. The comparison group will be farsighted babies who receive the current standard of care, namely no correction. The main outcome of the study will be whether there is a significant difference in the decrease of farsightedness between the two groups when the infants are 18 months of age. If emmetropization can be enhanced in very farsighted babies, the risk of developing crossed or lazy eye will be reduced. The lifelong need for spectacles, contact lenses, or refractive surgery for high amounts of farsightedness would also be reduced. Positive results might also make infant eye examinations more common and place a new therapeutic option in clinicians' hands.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date January 5, 2023
Est. primary completion date January 5, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 8 Weeks to 15 Weeks
Eligibility Inclusion Criteria: - Age: between 8 and 15 weeks at baseline examination - Either gender - Any ethnicity - Birthweight greater than 2500g - Normal pregnancy and delivery (including Cesarean section delivery but excluding serious complications or conditions such as eclampsia or rubella) - Hyperopia greater than or equal to +5.00 Diopters (D) in the spherical component of refractive error in one or both eyes measured with cycloplegic retinoscopy using 1% cyclopentolate - Infants with a refractive error of greater than or equal to +5.00D but less than or equal to +7.00D in the spherical component of refractive error will be randomized to treatment (partial correction with accommodative training) or observation only. - Infants with greater than +7.00D in the spherical component of refractive error will receive treatment Exclusion Criteria: - Astigmatism greater than 2.00D in either eye - Anisometropia greater than 1.50D (spherical equivalent) - History of strabismus surgery - History of difficulty with pupillary dilation - History of cardiac, liver, asthma, or other respiratory disease - History of ocular disease, retinal detachment, severe macular dragging, intraocular surgery, optic nerve hypoplasia, malformations of the eye, cortical visual impairment or active inflammation - History of hydrocephalus, Down syndrome, cerebral palsy, developmental delay, seizure disorders

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Glasses
Partial refractive correction in a pair of glasses.

Locations

Country Name City State
United States The Ohio State University Columbus Ohio

Sponsors (1)

Lead Sponsor Collaborator
Donald O Mutti, OD, PhD

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Central cycloplegic refractive error with retinoscopy The subject's central refractive error will be measured (in Diopters) with cycloplegic retinoscopy to determine if partial refractive correction and accommodative training can enhance emmetropization in highly hyperopic infants. Successful enhancement is defined as being an average of 1.75 Diopters less hyperopic than control subjects at 18 months. 18 months
Secondary Peripheral cycloplegic refractive error with SureSight autorefractor The subject's central and peripheral refractive error will be measured (in Diopters) with the SureSight autorefractor to determine if partial refractive correction and accommodative training can enhance emmetropization through modulation of ocular shape in highly hyperopic infants. 18 months
Secondary Accommodative response with PowerRefractor The subject's accommodative ability will be measured objectively with a PowerRefractor autorefractor to determine determine if partial refractive correction and accommodative training can enhance emmetropization through modulation of accommodation in highly hyperopic infants. 18 months
See also
  Status Clinical Trial Phase
Completed NCT06046209 - Comparing a Monthly Replacement Lens Versus a Daily Disposable Lens N/A
Completed NCT05656885 - Clinical Evaluation of Two Frequent Replacement Soft Spherical Contact Lenses N/A
Completed NCT02423109 - Bilateral Dispensing Study of Fanfilcon A Toric Versus Enfilcon A Toric Lenses N/A
Completed NCT01392950 - Clinical Study of Clariti Monthly Contact Lens N/A
Withdrawn NCT00765960 - Evaluation of Outcomes Using the Amo Advanced CustomVue Ilasik Procedure
Completed NCT00520689 - Multipurpose Disinfecting Solution Compatibility With a Silicone Hydrogel Contact Lens Phase 3
Completed NCT05538182 - Zimbabwe Eyecare And Learning(ZEAL):Formative Research on Hyperopia and Educational Outcomes in Primary School Children N/A
Enrolling by invitation NCT05976750 - Air Optix® Night and Day® Aqua Daily Wear
Completed NCT02575911 - Accuracy of LASIK Flaps Created With the LenSx® Femtosecond Laser - A Pilot Study N/A
Completed NCT05735990 - Retrospective Clinical Investigation of the Safety and Performance of 640PM Trifocal IOL Implantation in Patients With Cataract and/or Ametropia (Hyperopia, Myopia) and/or Presbyopia
Withdrawn NCT03671096 - Safety and Efficacy of the Transform™ Corneal Allograft for Hyperopia Correction N/A
Recruiting NCT02279446 - Development of a Validated Chart for Intermediate Vision Assessment N/A
Completed NCT02060539 - Multicenter Dispensing Study of Biofinity Lenses in Extended Range N/A
Completed NCT01951573 - Evaluation of a New Daily Disposable Multifocal Contact Lens Design N/A
Completed NCT01467557 - Daily Disposable Performance of 1•DAY ACUVUE® TruEye™ and 1•DAY ACUVUE® MOIST® With LACREON® TECHNOLOGY
Completed NCT01228591 - Pilot Dispensing Evaluation of a Plus Power Lens N/A
Completed NCT03722784 - Evaluation of Silicone Hydrogel Daily Wear Contact Lenses for Up to One (1) Month of Daily Wear N/A
Completed NCT03688672 - Apioc Contact Lens Feasibility N/A
Completed NCT05741450 - A Clinical Comparison of Two Soft Contact Lenses N/A
Completed NCT01912781 - Safety and Efficacy Evaluation of a New Contact Lens Disinfecting Solution in Gas Permeable Contact Lens Wearers N/A